Results 241 to 250 of about 92,350 (272)

Tocilizumab (Actemra) [PDF]

open access: yesHuman Vaccines and Immunotherapeutics, 2017
Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA).
Philip P Stapleton, Bhaskar Dasgupta
exaly   +4 more sources

Tocilizumab in transplantation

European Journal of Clinical Pharmacology, 2020
Tocilizumab, a monoclonal antibody directed against the IL-6 receptor, might block detrimental effects of IL-6 on transplantation. IL-6 plays a considerable role in cytokine storm after stem cell transplantation as well as graft versus host disease, and it has also been shown to be involved in solid organ allograft rejection; therefore, tocilizumab is ...
Banafsheh, Mosharmovahed   +4 more
openaire   +2 more sources

CT-P47/Tocilizumab-anoh: A Tocilizumab Biosimilar

Clinical Drug Investigation
CT-P47/tocilizumab-anoh (AVTOZMA®) is a biosimilar of reference tocilizumab, an IL-6R inhibitor. CT-P47 is approved for treating rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, Coronavirus disease 2019 and cytokine release syndrome in the USA and the EU. CT-P47 has similar
openaire   +2 more sources

Tocilizumab

Hospital Pharmacy, 2010
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy ...
Dennis J. Cada   +2 more
openaire   +1 more source

Tocilizumab in Patients Admitted to Hospital With COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial

Lancet, The, 2021
Laura Harrison   +2 more
exaly  

Home - About - Disclaimer - Privacy